GENEVA, SWITZERLAND, January 12, 2011 - Selexis SA, a Swiss-based biotechnology company offering technologies and services to enable improved drug discovery, development, and cGMP production, announced today that Selexis and Neogenix Oncology, Inc. (Neogenix) entered into a Commercial License Agreement to commercialize the high expression production cell line expressing Neogenix NPC-1C. Selexis had previously developed the high expression NPC-1C cell line for Neogenix under a Contract Cell Line Development Services Agreement.

Terms of the agreement were not disclosed.
“We are pleased that Neogenix has joined our growing list of clients moving forward with production cell lines generated by Selexis’ leading technologies and services.” said Dr. Igor Fisch, CEO of Selexis.

About Selexis:

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells – Selexis Genetic Elements™. Selexis has further developed platforms, to include: Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, and Selexis SURE Cell Line Development™.

About Neogenix Oncology

Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work in its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of ensituximab (NPC-1C antibody) in patients with metastatic pancreatic and colorectal cancer. For more information, please visit the company’s web site at www.neogenix.com.